RxDoctor Payments Data

Donald Huffman, DO

Family Medicine · Jefferson, NCNPI 1689201691

Payments from drug & device makers

$949in general payments, 2019–2025

Across 47 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$141
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$129
  • Amgen$96
  • Ardelyx, Inc.$81
  • AbbVie$65
  • Aimmune Therapeutics, Inc.$58
  • plus $379 from 11 others

What the payments were for

  • Food & beverage$949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$949 in reported general payments places this provider in the 65th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$110,745
Medicare patients
380
Services billed
2,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban89$80,159
OzempicSemaglutide47$66,792
JardianceEmpagliflozin40$34,187
RybelsusSemaglutide13$18,107
XareltoRivaroxaban11$15,777
EntrestoSacubitril/Valsartan19$13,414
MyrbetriqMirabegron17$11,962
JanuviaSitagliptin Phosphate16$10,683
FarxigaDapagliflozin Propanediol14$10,653
Breo ElliptaFluticasone/Vilanterol13$6,493
SymbicortBudesonide/Formoterol Fumarate13$3,698
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,946
Rosuvastatin Calcium309$2,576
Scopolamine13$2,137
SynthroidLevothyroxine Sodium22$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$44$84,89960 claims
Astellas Pharma US IncMyrbetriq$16$11,96217 claims
GSKBreo Ellipta$57$6,49313 claims
AbbVieSynthroid$65$1,56422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Jefferson

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →